12 completed, 8 unknown. 16 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 9, Unknown 7 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Respirent Pharmaceuticals Co Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Unknown | Respirent Pharmaceuticals Co Ltd. | 451 | 2023-01-30 | 2023-03-01 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-08-13 | 2021-08-26 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-01-18 | 2021-04-20 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals, FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK, Placebo - Asthma | Phase 3 | Completed | Respirent Pharmaceuticals Co Ltd. | 451 | 2020-12-09 | 2023-04-06 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-09-22 | 2021-01-20 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-09-01 | 2021-03-09 |
| A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 14 | 2020-08-24 | 2021-01-20 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-07-01 | 2021-03-09 |
| A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-10-01 | 2020-07-07 |
| Pooled Analysis FP_SX_250_50 Test, Reference - Asthma | Completed | Respirent Pharmaceuticals Co Ltd. | 82 | 2019-06-02 | 2021-03-10 | |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2019-05-21 | 2019-09-10 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC) Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 36 | 2019-03-12 | 2019-06-05 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2019-01-23 | 2019-03-27 |
| A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2018-11-20 | 2018-12-28 |
| A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Placebo - Asthma | Phase 3 | Completed | Respirent Pharmaceuticals Co Ltd. | 451 | 2018-10-02 | 2020-07-07 |
Asthma (8)
Fluticasone (20) · Salmeterol Xinafoate (17) · Fluticasone-Salmeterol Drug Combination (3)
Greece (20)
Ioannis Stefanidis, Professor (9) · Chrysoula Doxani, MD, MSc, PhD (6) · Athanasios Konstantinidis, Ass.Professor (1) · Chrysoula Doxani, Dr. (1) · Elias Zintzaras, Professor (1) · Konstantinos Kostikas, Associate Professor (1) · Konstantinos Kostikas, Professor (1)